trabodenoson + latanoprost

Trabodenoson + latanoprost is a fixed-dose combination of two ophthalmic drugs under investigation for the treatment of glaucoma and ocular hypertension. Trabodenoson is a selective adenosine A1 receptor agonist that lowers intraocular pressure (IOP) by increasing aqueous humor outflow through the trabecular meshwork, a mechanism distinct from currently approved therapies. Latanoprost is a prostaglandin F2 alpha analog that reduces IOP by increasing uveoscleral outflow. The combination aims to provide additive or synergistic IOP-lowering effects in patients with glaucoma or ocular hypertension who are insufficiently controlled on monotherapy. Both agents are administered as eye drops[3][4][5][8].